Acumen Pharmaceuticals, Inc. (ABOS) Misses Q2 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Acumen Pharmaceuticals, Inc. (ABOS) Misses Q2 EPS by 7c

BTIG Reiterates Buy Rating on Acumen Pharmaceuticals, Inc. (ABOS)

August 14, 2024 6:12 AM EDT

BTIG analyst Thomas Schrader reiterated a Buy rating and $11.00 price target on Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS).

The analyst comments "Enrolling a trial with a placebo arm when an active commercial drug is available is historically challenging, so we see Acumen's comments about the rapid enrollment of the P2 trial for Sabirnetug as very encouraging. Talking with management, both the therapeutic premise of a safer antibody that may also be more... More